Compare AIHS & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIHS | VIVS |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | China | United States |
| Employees | N/A | 13 |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.0M |
| IPO Year | 2017 | N/A |
| Metric | AIHS | VIVS |
|---|---|---|
| Price | $1.40 | $1.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.6K | ★ 168.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,389,072.00 | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.25 | $1.42 |
| 52 Week High | $8.26 | $5.30 |
| Indicator | AIHS | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 65.87 | 45.31 |
| Support Level | $1.12 | $1.75 |
| Resistance Level | $1.42 | $2.17 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 85.74 | 15.56 |
Senmiao Technology Ltd is a holding company. Along with its subsidiaries, it is engaged in facilitating automobile transactions and offering related services. The group's business activities include providing car rental services to individual customers with lease term no more than twelve months; leasing and servicing of new energy vehicles; offering services to automobile purchasers throughout the purchase process; providing management and related services to Partner Platforms and other companies; automobile financing; and providing other related supporting services to customers. The majority of the group's revenue is generated from its automobile rental business.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.